# INTERVIEW: SkinBioTherapeutics Plc Contract extension accelerates development work

- Link: https://www.directorstalkinterviews.com/skinbiotherapeutics-plc-contract-extension-accelerates-development-work/412729709
- Published: 2017-05-25T07:42:43+01:00
- Author: Giles Arbor

**SkinBioTherapeutics Plc** (LON:SBTX) CEO Dr Catherine O’Neill talks to DirectorsTalk
about the extension of a contract with the University of Manchester. Catherine explains
the purpose and audience of SkinBiotix, how the company will benefit from the extension
of the research contract, the importance of being labelled ‘dermatologically tested’
and what investors should be looking out for in terms of news flow.

SkinBioTherapeutics Plc is a life science company focused on skin health. The Company’s
proprietary platform technology, SkinBiotix®, is based upon discoveries made by 
CEO Dr. Catherine O’Neill and Professor Andrew McBain. The company’s platform applies
research discoveries made on the activities of lysates derived from probiotic bacteria
when applied to the skin. The Company has shown that the SkinBiotix® platform can
improve the barrier effect of skin models, protect skin models from infection and
repair skin models. Proof of principle studies have shown that the SkinBiotix® platform
has beneficial attributes applicable to each of these areas. The company received
seed funding from the Tech Transfer office of the University of Manchester for the
discovery of SkinBiotix®. The platform was subsequently spun out of the University
of Manchester in March 2016 and was funded by OptiBiotix Health Plc (LON:OPTI).

Share on: